Walgreens helped spread unneeded opioids throughout Kentucky as both pharmacy chain and distributor, the state's attorney general said in a lawsuit filed Thursday, allegedly cultivating a public health nightmare that has killed Kentuckians, defrauded Medicaid and spurred an armed-robbery epidemic.
The Patent Trial and Appeal Board on Thursday agreed to review the entirety of a Biogen Inc. patent covering its lymphomas biologic Rituxan, and shot down the drugmaker’s attempt to apply the board’s General Plastic decision to instances where follow-up petitions were filed by different companies.
President Donald Trump’s decision to impose punitive tariffs on Chinese technology in a squabble over intellectual property policy arrived with a wrinkle as the administration primed one set of duties for July while keeping another batch for the future, adding a new layer of intrigue to the sprawling trade fight.
Ten firms are slated to guide 10 initial public offerings projected to raise about $1.3 billion during the week of June 18, representing a lineup dominated by biotechnology issuers plus a real estate investment trust as IPO season hits a busy stretch before the July 4 holiday.
For the third time, a Massachusetts jury has decided that Boston Scientific was not at fault for the side effects of its pelvic mesh products and properly warned one of the thousands of women who have sued manufacturers of the transvaginal slings.
Private equity-backed tax automation company Avalara Inc. saw shares soar in first-day trading on Friday after raising $180 million in an initial public offering that priced better than expected, leading three issuers whose shares debuted following IPOs that raised $377 million combined.
It's been two years since the U.S. Supreme Court tossed a firecracker into the world of False Claims Act litigation with its decision in Universal Health Services v. Escobar, which explained how courts should gauge whether regulatory violations were "material" to government reimbursement. Here, attorneys tell Law360 how the decision has played out and what lies ahead.
Theranos Inc. ousted founder Elizabeth Holmes as CEO as she and the company’s former chief operating officer were indicted Friday on charges they defrauded investors and doctors with blood testing technology the pair knew didn’t work.
GI Partners, led by Paul Hastings LLP, revealed plans Friday to pick up donor sperm and egg bank California Cryobank and stem cell collection and storage company Cord Blood Registry in a pair of separate deals before merging the two into a top player in the stem cell storage and reproductive tissues services market.
The U.S. House of Representatives has voted to crack down on synthetic analogues for illegal drugs, passing a bill Friday that would give the Drug Enforcement Administration more ability to schedule and ban drugs engineered to closely mimic existing illegal substances.
Honigman Miller Schwartz and Cohn LLP has named a health care fraud pro to co-chair its white collar practice, Arnold & Porter has scored an attorney fresh out of the U.S. Food and Drug Administration, and another health expert has joined GrayRobinson PA.
President Donald Trump moved ahead Friday with tariffs that will eventually cover about $50 billion worth of Chinese goods as punishment for the nation’s restrictive intellectual property rules, targeting touch screens, steel components, medical devices and scores of other items in an escalating trade battle.
A Georgia federal judge largely refused Thursday to let a group of pharmaceutical companies out of a nearly decade-old antitrust multidistrict litigation from the Federal Trade Commission and private parties alleging that they conspired to keep generic competitors for testosterone drug AndroGel off the market.
New guidance from the U.S. Patent and Trademark Office suggests that patents on methods of treating disease should usually be considered patent-eligible, freeing patent holders from having to grapple with the convoluted eligibility analysis patents must often face, attorneys say.
Counsel for AndroGel users suing AbbVie Inc. in a multidistrict litigation over injuries allegedly caused by testosterone replacement therapy drugs asked an Illinois federal judge to slap the company with nearly $500,000 in sanctions Wednesday, claiming AbbVie misused a records-collecting process to challenge nearly 1,000 suits.
Australian medical device company Sirtex Medical on Thursday said it will scrap plans to be sold to Varian Medical Systems to instead pursue a roughly AU$1.87 billion ($1.4 billion) cash offer from China Grand Pharmaceutical and Healthcare Holdings and a Paul Hastings-advised affiliate of CDH Investments.
Indirect buyers of the stroke prevention medicine Aggrenox on Wednesday slammed a request by six insurance companies to opt out hundreds of potential class members from a $54 million settlement agreement over an alleged pay-for-delay scheme, saying the companies have failed to show they are authorized to make such a request.
A New York state judge has thrown out a former Cincinnati Reds draft pick's lawsuit accusing MLB of defamation and interfering with his baseball clinic, rejecting his third attempt to go after the league.
The Texas Judicial Panel on Multidistrict Litigation has agreed to consolidate 16 cases brought by Texas counties alleging opioid makers and distributors including Purdue Pharma LP and McKesson Corp. made false and misleading statements about the drugs.
A Johnson & Johnson customer urged the Third Circuit on Thursday to revive her putative class action over the alleged health hazard associated with the company’s talc-based baby powder, arguing she wouldn’t have purchased the product had she known it could raise her chances of getting ovarian cancer.
In UCB v. Accord, the Federal Circuit affirmed that claims covering a pharmaceutical compound were not invalid for obviousness-type double patenting. This case provides guidance on the obviousness and obviousness-type double patenting analyses in chemical compound cases, say attorneys at Paul Hastings LLP.
Despite the partiality some courts have shown to live video testimony, it provides no advantages — and several disadvantages — over the tried-and-true method of videotaped depositions, say attorneys with Skadden Arps Slate Meagher & Flom LLP.
"Uncivil Warriors: The Lawyers' Civil War," by Peter Hoffer, is a new book about the involvement of lawyers on both sides in the American Civil War. The discussion is enlightening and often fascinating, but falls short in several key areas, says Federal Circuit Judge Evan Wallach.
Recently signed into law by the president, the federal Right to Try Act creates a framework for patients to access investigational new drug products. But it comes in the wake of a majority of states passing their own "right to try" laws, creating the potential for a conflict between state laws, the U.S. Food and Drug Administration’s expanded access regulations and federal statutes, say attorneys with Morgan Lewis & Bockius LLP.
Connecting with potential prospects is now more challenging due to the EU General Data Protection Regulation, meaning that law firm microsites, blogs and social media will become more valuable than ever. The firms that deploy them strategically will increase their relative visibility and accelerate the rebuilding of their opt-in distribution lists, says Stephan Roussan of ICVM Group.
The judge in the national opioid multidistrict litigation recently ordered lawyers to disclose whether their cases are financed by third parties. This has drawn attention to courts’ responsibility to address problems surrounding third-party litigation funding, but a uniform funding disclosure requirement would be more effective, says Alex Dahl of Strategic Policy Counsel PLLC.
The U.S. Food and Drug Administration recently launched an initiative to reduce the use of e-cigarettes and related products by young people. While it is not clear how extensively the FDA will try to restrict electronic nicotine delivery systems and e-liquids, forthcoming proposals may be substantial, say Azim Chowdhury and Benjamin Wolf of Keller & Heckman LLP.
The U.S. Supreme Court’s decision in Murphy v. National Collegiate Athletic Association was focused on sports betting but could be construed as conferring substantially more power on states in general, on issues including gun control, marijuana legalization and sanctuary cities, says Cory Lapin of Manning Gross & Massenburg LLP.
The growth of litigation funding has only increased the controversy surrounding it. Looking to move beyond the rhetoric for and against the practice, attorney and investment analytics expert J.B. Heaton, of J.B. Heaton PC and Conjecture LLC, attempts an objective analysis of the underlying economics of the litigation funding arrangement.
Courts are acknowledging a shifting consumer preference toward electronic mediums. Proposed changes to Rule 23, scheduled to take effect at the end of this year, will officially provide for the use of electronic notice in class actions — a change that could save parties a significant amount of money, say Brandon Schwartz and Maggie Ivey of Garden City Group LLC.